3 apos; application of sialic acid lactose in preparation of medicine for improving cardiac remodeling and dysfunction

Through 3'-sialic acid lactose as a biomarker and therapeutic agent, the diagnostic and therapeutic problems of cardiac remodeling are solved, significantly alleviating cardiac myocyte hypertrophy and fibrosis, improving cardiac function, and providing a new strategy for treating cardiac remodeling.

CN119082289APending Publication Date: 2024-12-06SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411210430.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reverse or prevent the heart remodeling process, leading to the progress of heart failure and lacking new therapeutic targets and strategies.

Method used

3'-sialic acid lactose as a biomarker used to diagnose and treat cardiac remodeling, significantly alleviates cardiac hypertrophy and fibrosis through exogenous supplementation, and restores angiotensin II-induced cardiac remodeling-related gene expression to normal levels.

Benefits of technology

3'-sialic acid lactose significantly improves cardiac organic lesions, providing new directions and strategies for treating cardiac remodeling, which can effectively reduce cardiac myocyte hypertrophy and fibrosis and improve cardiac function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082289A_ABST
    Figure CN119082289A_ABST
Patent Text Reader

Abstract

The invention discloses an application of 3 '-sialic acid lactose in preparation of a medicine for improving heart remodeling and dysfunction, belongs to the technical field of biological medicine, and finds that the 3'-sialic acid lactose can be used as a biomarker to prepare a product for diagnosing the heart remodeling process through research for the first time. In the heart remodeling process, the 3 '-sialic acid lactose can improve organic pathological changes of the heart, the exogenous supplementation of the 3'-sialic acid lactose can effectively relieve myocardial cell hypertrophy and myocardial fibrosis, and can restore heart remodeling related gene expression to a normal level, so that the effect of improving the heart remodeling is remarkable, and the application of the 3 '-sialic acid lactose in the heart remodeling process is broad. The invention can be used for preparing a medicine for treating heart remodeling, and provides a new research direction and treatment strategy for heart remodeling.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of 3'-sialyllactose in preparing medicines for improving cardiac remodeling and dysfunction. Background Art

[0002] Heart failure is a clinical syndrome caused by cardiac dysfunction, and its morbidity and mortality rates are increasing. Heart failure is the terminal stage of many heart diseases, triggered by abnormal cardiac structure or function due to various reasons, manifested as a decrease in the heart's ability to pump blood, and an inability to fully supply the oxygen and nutrients needed by various parts of the body. Cardiac hypertrophy is usually a direct cause of heart failure, and cardiac remodeling is a key process leading to the deterioration of heart failure. The specific manifestations are: abnormal hypertrophy of myocardial cells, involving an increase in the size of myocardial cells, that is, cardiac hypertrophy; on the other hand, it is manifested in changes in cardiac structure.

[0003] Traditional treatments for cardiac remodeling include medication, surgical intervention, and lifestyle adjustments, such as reducing salt intake and maintaining moderate exercise. Although these methods can relieve symptoms and improve quality of life to a certain extent, they usually cannot fundamentally reverse the process of cardiac remodeling or prevent the progression of the disease. Therefore, finding new therapeutic targets and developing new therapeutic strategies are of great significance for the treatment of cardiac remodeling.

[0004] In recent years, researchers have paid more and more attention to the role of nutritional factors in heart disease, especially those nutrients with the potential to regulate metabolism and cardiac function. 3'-Sialyl lactose (3'-SL) is an oligosaccharide that exists in high abundance in breast milk, especially in early breast milk, and plays an important role in the growth of infants. It has broad application prospects in the food industry, especially in the infant formula industry. Whether 3'-Sialyl lactose has the effect of treating cardiac remodeling and improving organic heart lesions has not been reported. Summary of the invention

[0005] In view of the above-mentioned prior art, the purpose of the present invention is to provide the use of 3'-sialyllactose in the preparation of drugs for improving cardiac remodeling and dysfunction. The present invention has found that in the process of cardiac remodeling, 3'-SL is the only metabolite that changes significantly. Exogenous 3'-SL can significantly improve myocardial cell hypertrophy, reduce cardiac fibrosis, and restore the expression of genes related to cardiac remodeling caused by angiotensin II to normal levels. These results show that 3'-sialyllactose plays an important role as a biomarker in the preparation of products for diagnosing the progress of cardiac remodeling, and is expected to become a new target for the treatment of cardiac remodeling.

[0006] To achieve the above object, the present invention adopts the following technical solution: In a first aspect, the present invention provides the use of 3'-sialyllactose as a biomarker in the preparation of a product for diagnosing the process of cardiac remodeling.

[0007] The cardiac remodeling is specifically manifested as abnormal hypertrophy of cardiomyocytes or changes in cardiac structure.

[0008] The abnormal hypertrophy of cardiomyocytes is induced by angiotensin II.

[0009] In a second aspect, the present invention provides the use of a reagent for detecting 3'-sialyllactose in the preparation of a product for diagnosing the process of cardiac remodeling.

[0010] The reagent for detecting 3'-sialyllactose is any one of a standard for detecting 3'-sialyllactose, a primer for detecting 3'-sialyllactose, a probe for detecting 3'-sialyllactose, or a protein recognition receptor that specifically binds to 3'-sialyllactose.

[0011] The third aspect of the present invention provides the use of 3'-sialyllactose in preparing a drug for treating cardiac remodeling.

[0012] Beneficial effects of the present invention: The present invention is the first to study and discover that 3'-sialyllactose can be used as a biomarker to prepare products for diagnosing the process of cardiac remodeling. In the process of cardiac remodeling, 3'-sialyllactose can improve organic cardiac lesions. Exogenous supplementation of 3'-sialyllactose can effectively reduce myocardial cell hypertrophy, reduce myocardial fibrosis, and restore the expression of cardiac remodeling-related genes to normal levels. It has a significant effect in improving cardiac remodeling and can be used to prepare drugs for treating cardiac remodeling. The present invention provides a new research direction and treatment strategy for cardiac remodeling. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 is the distribution of the patient's plasma metabolome data; Figure 1 Middle a is the distribution of cardiac function status with left ventricular ejection fraction below 40%, 40% to 50%, and above 50%; Figure 1 (b) shows the distribution of cardiac remodeling status in patients with normal geometry, cardiac remodeling, condensed hypertrophy, and eccentric hypertrophy.

[0014] Figure 2 Detection of relative abundance of metabolites.

[0015] Figure 3 Pathway analysis for differential metabolites.

[0016] Figure 4 Venn diagram of metabolites associated with cardiac function and cardiac remodeling.

[0017] Figure 5is: relative intensity detection of 3'-sialyllactose; wherein, Figure 5 Middle a is the relative intensity detection of 3'-sialyllactose in patients with normal geometry, cardiac remodeling, condensed hypertrophy, and eccentric hypertrophy; Figure 5 Middle b shows the relative intensity detection of 3'-sialyllactose when the left ventricular ejection fraction is less than 40%, 40% to 50%, and more than 50%.

[0018] Figure 6 is: Correlation analysis of 3'-sialyllactose levels; wherein, Figure 6 a in the figure is the correlation analysis between 3'-sialyllactose level and left ventricular mass index (LVMI); Figure 6 (b) shows the correlation analysis between 3'-sialyllactose level and left ventricular ejection fraction (LVEF).

[0019] Figure 7 Figure 1: Schematic diagram of animal experiment design.

[0020] Figure 8 These are hematoxylin-eosin staining images of heart tissues in different groups.

[0021] Fig. 9 Schematic diagram of the cross-sectional area of ​​myocardial cells in different groups of cardiac tissue; Fig. 9 Middle a is a WGA staining image showing the cross-sectional area of ​​myocardial cells in heart tissues of different groups. Fig. 9 Middle b shows the statistical results of quantitative analysis of the cross-sectional area of ​​cardiomyocytes in different groups of cardiac tissue.

[0022] Fig.10 The staining images of different groups of cardiac tissues in the perivascular and interstitial areas; Fig.10 A in the middle is a tri-color staining image of the perivascular and interstitial areas of cardiac tissues in different groups. Fig.10 Middle B is the picropicrosirius red staining of the perivascular and interstitial areas of cardiac tissues in different groups.

[0023] Fig.11 is the mRNA expression level in the heart tissue of mice in different groups; Fig.11 Middle A shows the mRNA expression levels of Collal, Colla2, Col3a, SPPl and Eln in the heart tissues of mice in different groups; Fig.11 Middle B shows the mRNA expression levels of Nppa and Nppb in the heart tissues of mice in different groups.

[0024] Fig.12 Analysis of protein expression levels in cardiac tissues of different groups; Fig.12A in the middle is a Western blot analysis of collagen I, collagen III, β-MyHC (β-myosin heavy chain) and TGF-βl (transforming growth factor-βl) in cardiac tissues of different groups, and GAPDH was used as a loading control; Fig.12 Middle B is the quantitative analysis of collagen I, collagen III, B-MyHC and TGF-βl proteins in heart tissues of different groups.

[0025] Fig.13 It is the analysis diagram of H9C2 cells in different groups; Among them, Fig.13 Middle A is the WGA staining of H9C2 cells in different groups. Fig.13 Middle B is a quantitative analysis of the cell cross-sectional area of ​​H9C2 cells in different groups.

[0026] Fig.14 Real-time quantitative polymerase chain reaction (RT-qPCR) analysis of Col1a1, Col3a1 Nppa and Nppb mRNA expression levels in H9C2 cells in different groups.

[0027] Fig.15 is the expression level of proteins in H9C2 cells in different groups; Fig.15 A is a Western blot analysis of collagen I, collagen III, β-MyHC (β-myosin heavy chain), and TGF-βl (transforming growth factor-βl) in H9C2 cells in different groups, and GAPDH was used as a loading control; Fig.15 Middle B is the quantitative analysis of collagen I and collagen III proteins in H9C2 cells in different groups; Fig.15 Center C shows the quantitative analysis of β-MyHC and TGF-βl proteins in H9C2 cells in different groups. DETAILED DESCRIPTION

[0028] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0029] As mentioned above, heart failure is a clinical syndrome caused by cardiac dysfunction, and its incidence rate is increasing year by year. Cardiac remodeling is the key process leading to the deterioration of heart failure. The specific manifestations of cardiac remodeling are abnormal increase in the volume of myocardial cells and changes in cardiac structure. Actively searching for new therapeutic targets and developing new therapeutic strategies are of great significance for the treatment of heart failure and cardiac remodeling.

[0030] Based on this, the present invention provides the use of 3'-sialyllactose in the preparation of a drug for improving cardiac remodeling and dysfunction. By performing metabolite difference analysis in people with concentric remodeling (CR), concentric hypertrophy (CH), eccentric hypertrophy (EH) and normal geometry (NG), it is found that 3'-Sialyllactose is the only differential metabolite showing a significant change trend, and its level is significantly increased in patients with cardiac hypertrophy and cardiac structural changes. Since the left ventricular mass index (LVMI) is positively correlated with the degree of left ventricular hypertrophy, and the left ventricular ejection fraction (LVEF) is negatively correlated with the severity of cardiac function, the experimental detection results show that the level of 3'-sialyllactose is positively correlated with the left ventricular mass index and negatively correlated with the left ventricular ejection fraction. Therefore, 3'-sialyllactose can be used as a beneficial medium and a biomarker for detecting the process of cardiac remodeling.

[0031] To confirm whether the significantly increased level of 3'-sialyllactose in patients with cardiac hypertrophy and cardiac structural changes is due to compensatory increase after stress, a mouse disease model was further constructed to determine its effect on cardiac remodeling. The gene expression levels of type I collagen a1 (Col1a1), type I collagen a2 (Col1a2), type III collagen (Col3a), secretory pyrophosphate protein 1 (Sppl) and elastin (Eln) in mouse heart tissue indicated the degree of fibrosis in the heart tissue of mice in different groups, and the gene expression levels of natriuretic peptide a (Nppa) and natriuretic peptide b (Nppb) indicated the degree of myocardial hypertrophy in the heart tissue of mice in different experimental groups. Collagen I, Collagen III, B-MyHC (β-myosin heavy chain) and TGF-βl (transforming growth factor-βl) can reflect the degree of cardiac remodeling. The present invention has confirmed through animal experiments that 3'-sialyllactose significantly reduces cardiac hypertrophy induced by angiotensin II, reduces myocardial fibrosis, and can prevent the upregulation of angiotensin II-induced cardiac remodeling-related genes, and can better improve cardiac remodeling.

[0032] The following detailed description is for illustrative purposes only and is intended to provide further explanation of the present application, rather than to limit the scope of the present invention.

[0033] Example 1: 3'-sialyllactose can be used as a biomarker to detect cardiac remodeling process In this example, the left ventricular ejection fraction (EF) of 433 patients with acute coronary syndrome (ACS) was collected. To evaluate cardiac function, cardiac structural parameters were obtained by echocardiography. The ACS population was divided into four groups based on the changes in left ventricular mass index (LVMI) and left ventricular relative wall thickness (RWT): normal geometry (NG), cardiac remodeling (CR), concentric hypertrophy (CH), and eccentric hypertrophy (EH). The proportions of each group are shown in Figure 1 shown.

[0034] By detecting the relative abundance of metabolites in the plasma of four groups of patients with cardiac function ( Figure 2 ), and analyzed the pathways of differential metabolites related to cardiac function ( Figure 3 ), the results showed that 3'-sialyllactose was the only significantly changed differential metabolite. Further, by performing a Venn diagram analysis of metabolites related to cardiac function and cardiac remodeling ( Figure 4 ) found that in the stage of heart failure, 168 downregulated metabolites were significantly downregulated, of which 48 were significantly correlated with left ventricular ejection fraction (LVEF) (i.e., decreased heart function), 2 metabolites were significantly correlated with aggravated cardiac remodeling, and only 3'-Sialyllactos was both related to cardiac function and significantly correlated with cardiac remodeling. Subsequently, the relative intensity of 3'-sialyllactose in the patients was measured ( Figure 5 ), the results showed that compared with people with normal geometry, the level of 3'-sialyllactose was significantly increased. With the increase of cardiac remodeling and the severity of cardiac function, the level of 3'-sialyllactose gradually increased overall. The correlation between 3'-sialyllactose level and left ventricular hypertrophy index and left ventricular ejection fraction was analyzed ( Figure 6 ), the test results showed that the level of 3'-sialyllactose was positively correlated with the left ventricular hypertrophy index and negatively correlated with the left ventricular ejection fraction (reflecting cardiac function), that is, 3'-sialyllactose played a key role in cardiac hypertrophy and heart failure, and could be used as a biomarker for detecting the process of cardiac remodeling.

[0035] Example 2: Therapeutic effect of 3'-sialyllactose on angiotensin II-induced myocardial hypertrophy mouse model (1) Experimental methods: Eighteen healthy, 8-week-old male C57BL / 6 mice were selected and divided into a control group (Control), a model group (AngⅡ) and an experimental group (Ang Ⅱ+3'-sialyllactose), with 6 mice in each group.

[0036] The mice in the control group were implanted with a micro-osmotic pump (Alzet model 1002) under 2% isoflurane anesthesia, and normal saline (Saline) was continuously administered at 1.5 mg / kg / d through the Alzet micro-osmotic pump, and 600 nmol of phosphate-buffered saline (PBS) was orally administered (orally) once a day.

[0037] The mice in the model group were implanted with a micro-osmotic pump (Alzet model 1002) under 2% isoflurane anesthesia. Angiotensin II (AngII) was continuously administered at 1.5 mg / kg / d through the Alzet micro-osmotic pump, and 600 nmol of phosphate buffer was administered orally (orally) once a day.

[0038] The mice in the experimental group were implanted with a micro-osmotic pump (Alzet model 1002) under 2% isoflurane anesthesia, and angiotensin II (AngII) was continuously administered at 1.5 mg / kg / d through the Alzet micro-osmotic pump, and 600 nmol of 3'-sialyllactose was orally administered (orally gavage) once a day.

[0039] After two weeks, the mice were anesthetized using the anesthetic drugs ketamine and ketamine (at ratios of 100 mg / kg and 10 mg / kg, respectively), and the mouse hearts were removed for histological staining analysis, real-time quantitative polymerase chain reaction analysis of related gene expression, Western blot, and quantitative analysis of corresponding proteins.

[0040] Among them, the ergot agglutinin staining (WGA) experiment of heart tissue includes the following steps: 1) Drying and dewaxing: Place the paraffin sections of the heart tissue in a 60℃ oven for 1 hour to melt the paraffin and prevent them from falling off. Then dewax to the water phase in the following order: xylene I, 5 minutes; xylene II, 5 minutes; xylene III, 5 minutes; anhydrous ethanol, 5 minutes; 95% ethanol, 5 minutes; 85% ethanol, 5 minutes; 75% ethanol, 5 minutes, and then rinse with running water for 10 minutes. 2) Add WGA working solution (1:200) and incubate in the dark for 1 hour; 3) Wash with PBS three times, 3 minutes each time, and seal the slides with anti-fluorescence quenching sealing solution. Be careful not to create bubbles. After drying, take pictures.

[0041] The hematoxylin-eosin staining experiment includes the following steps: 1) After drying and dewaxing (same steps as WGA staining), stain the nucleus with hematoxylin for 5 minutes, then differentiate with hydrochloric acid alcohol differentiation solution for 5 seconds, then quickly rinse in a slow stream of tap water for 10 minutes, and use the substance in the tap water to turn it back to blue; 2) Stain the cytoplasm with eosin for 5 minutes, wash off the floating color with tap water and then quickly start dehydration and transparency. The dehydration and transparency treatments are 75% ethanol for 5 minutes; 85% ethanol for 5 minutes; 95% ethanol for 5 minutes; anhydrous ethanol for 5 minutes; xylene I for 5 minutes; xylene II for 5 minutes; xylene III for 5 minutes; 3) Sealing: Seal the slides quickly with neutral gum, wait for them to dry, and then take photos.

[0042] The Masson trichrome staining experiment includes the following steps: 1) After drying and dewaxing (same steps as WGA staining), place the slices in Bouin's solution at 4°C overnight. After overnight, rinse the tissue slices with tap water until the yellow color fades; 2) Ponceau staining for 30 minutes, drop double distilled water on the slide to wash away the Ponceau red, differentiate with phosphomolybdic acid for 1 minute, and then stain with aniline blue for 3 minutes, drop double distilled water on the slide to wash away the aniline blue; 3) After dehydration and transparency (same as hematoxylin-eosin staining), quickly seal the slide with neutral gum and take photos after drying.

[0043] The Picrosirius Red staining experiment includes the following steps: 1) After drying and dewaxing (same steps as WGA staining), the sections were placed in 0.1% picric acid picrosirius red staining solution for 1 hour and rinsed with running water for 5 minutes; 2) After dehydration and transparency (same as hematoxylin-eosin staining), quickly use neutral gum to seal the slides, wait until they are dry, and then take photos.

[0044] (2) Experimental results: Hematoxylin-eosin staining of heart tissue ( Figure 8 ), schematic diagram of the cross-sectional area of ​​myocardial cells in different groups of cardiac tissue ( Fig. 9 ), staining images of perivascular and interstitial areas of cardiac tissues in different groups ( Fig.10 ) showed that 3'-sialyllactose has an effect on angiotensin II-induced cardiac structural changes, can alleviate angiotensin II-induced cardiac tissue hypertrophy, reduce the cross-sectional area of ​​myocardial cells, and alleviate fibrosis around the heart and blood vessels.

[0045] The expression levels of Collal, Colla2, Col3a, SPPl and Eln genes reflecting the degree of fibrosis in the heart tissue of mice in different groups ( Fig.11 Middle A), Nppa and Nppb gene expression levels reflecting the degree of myocardial hypertrophy ( Fig.11(B) Analysis of the expression levels of Collagen I, Collagen III, B-MyHC (β-myosin heavy chain) and TGF-βl (transforming growth factor-βl) proteins in cardiac tissue ( Fig.12 ) The test results showed that 3'-sialyllactose treatment reversed the changes in expression of cardiac remodeling genes induced by angiotensin II, and supplementation of 3'-sialyllactose could prevent angiotensin II-induced cardiomyocyte hypertrophy and alleviate the upregulation of cardiac remodeling-related genes.

[0046] Example 3: Protective effect of 3'-sialyllactose on H9C2 cardiomyocytes in a simulated cardiac injury environment H9C2 cardiomyocytes were cultured in DMEM medium containing 10% fetal bovine serum at 37°C and 5% CO 2 H9C2 cardiomyocytes were cultured under the conditions of 10% and 20% saturation. H9C2 cardiomyocytes were harvested and divided when the confluence was close to 80-90% to maintain cell growth activity. After being seeded in a 12-well cell culture plate, H9C2 cardiomyocytes were first cultured normally until the density was close to the appropriate density. Serum starvation treatment was performed for 16 hours to synchronize the cell cycle.

[0047] In order to evaluate the effect of 3'-sialyllactose on cardiac remodeling, H9C2 cardiomyocytes were divided into control group, treatment group (Ang Ⅱ), experimental group 1 (Ang Ⅱ+5nM 3'-sialyllactose), and experimental group 2 (Ang Ⅱ+10nM 3'-sialyllactose). The cells in experimental groups 1 and 2 were pretreated with 3'-sialyllactose for 24 hours and then treated with 1μmol angiotensin II for 24 hours. The control group was treated with 1μmol saline for 48 hours. The treatment group was treated with 1μmol angiotensin II for 48 hours. Subsequently, H9C2 cardiomyocytes were subjected to histological staining observation and quantitative analysis of cell area.

[0048] WGA staining of H9C2 cells in different groups ( Fig.13 Middle A), Fig.13 Middle B is a quantitative analysis of the cell cross-sectional area of ​​H9C2 cells in different groups ( Fig.13 Real-time quantitative polymerase chain reaction (RT-qPCR) analysis of Col1a1, Col3a1Nppa and Nppb mRNA expression levels in H9C2 cells in different groups ( Fig.14 ), protein expression levels in H9C2 cells in different groups ( Fig.15) The experimental results showed that at the H9C2 cell experimental level, 3'-sialyllactose significantly reduced the hypertrophy of H9C2 cardiomyocytes induced by angiotensin II. 3'-sialyllactose can prevent the upregulation of genes related to cardiac remodeling induced by angiotensin II.

[0049] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification made within the spirit and principle of the present application shall be deemed to be appropriate. Equivalent replacements, improvements, etc. should all be included in the protection scope of this application.

Claims

1. Application of 3'-sialyllactose as a biomarker in the preparation of products for diagnosing cardiac remodeling processes.

2. The use according to claim 1, characterized in that: The cardiac remodeling is specifically manifested as abnormal hypertrophy of cardiomyocytes or changes in cardiac structure.

3. The use according to claim 2, characterized in that: The abnormal hypertrophy of cardiomyocytes or changes in cardiac structure are induced by angiotensin II.

4. Use of a reagent for detecting 3'-sialyllactose in the preparation of a product for diagnosing the process of cardiac remodeling.

5. The use according to claim 4, characterized in that: The reagent for detecting 3'-sialyllactose is at least one of a standard for detecting 3'-sialyllactose, a primer for detecting 3'-sialyllactose, a probe for detecting 3'-sialyllactose, or a protein recognition receptor that specifically binds to 3'-sialyllactose.

6. Use of 3'-sialyllactose in the preparation of drugs for treating cardiac remodeling.